| Price | $1120.22 |
| Year Range | $848.5 – $1280.34 |
| Market Cap | $1,024B |
| PE Ratio | 38.61 |
| Industry | Drug Manufacturers |
What Is Eli Lilly and Company’s AI Stock Analysis?
Eli Lilly and Company’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Eli Lilly and Company’s momentum in near-real time.
Eli Lilly and Company (LLY) has an AltIndex AI Score of 51/100, currently a Hold signal. The AI Score distills Eli Lilly and Company's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Eli Lilly and Company’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Eli Lilly and Company — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving LLY’s AI Score?
Fundamentals
Revenue for the last quarter was $23B. This is an increase of 16.04% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 47.67%, suggesting positive year-over-year growth. Net income for the last quarter was $7.1B. This represents a decrease of 4.07% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of 25.34%, suggesting positive year-over-year growth. Ebitda for the last quarter was $9.25B. This represents a decrease of 4.58% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of 23.23%, suggesting positive year-over-year growth. The current P/E ratio is 38.61. This may be considered high, potentially indicating overvaluation and a bearish outlook. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Eli Lilly and Company’s earnings and insider transactions.
Technicals
Today's stock price is $1,125.20. This represents a decrease of 4.96% compared to a month ago, which may be concerning in the short-term. Compared to a year ago, there is an increase of 50.85%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $1,153.37, which is lower than the previous SMA10 of $1,158.31. This suggests a potential downward trend in price movement. The RSI is 46.9, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Eli Lilly and Company has an estimated 732 open positions. This number is down by -20% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Eli Lilly and Company is neutral. Eli Lilly and Company has an estimate of 7.5M visitors to their webpage. The number of visitors is up by 5% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Eli Lilly and Company’s job postings, web traffic and app downloads.
Sentiment & social
Eli Lilly and Company has 95,000 followers on their Instagram page. The number of followers is up by 14% in the last couple of months, indicating an increased interest in the company. Eli Lilly and Company has 150,000 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Eli Lilly and Company’s market sentiment.
Frequently Asked Questions: Eli Lilly and Company AI Stock Analysis
Eli Lilly and Company's AltIndex AI Score is 51/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Eli Lilly and Company a Hold (51/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Eli Lilly and Company — company overview, fundamentals, technicals and alternative data, with a recommendation. See the LLY AI Score or sign up to read the full thesis.
